This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
by Zacks Equity Research
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.
Aeglea Initiates Lung Cancer Combination Study With Keytruda
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
Acorda Files Parkinson's Drug Marketing Application in EU
by Zacks Equity Research
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug
by Zacks Equity Research
Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer
by Zacks Equity Research
AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.
Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus
by Zacks Equity Research
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
Cancer Space Takes Giant Strides: Are Patients Benefiting?
by Kinjel Shah
The new cancer treatments are probably not doing enough to cure patients or help them live longer or better.
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
by Zacks Equity Research
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails
by Zacks Equity Research
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
AstraZeneca's Forxiga Label Expansion Filing Accepted in EU
by Zacks Equity Research
AstraZeneca's (AZN) submission for label expansion of diabetes drug Forxiga accepted by the European Medicines Agency.
Are Alzheimer's-Focused Stocks Set for a Financial Windfall?
by Zacks Equity Research
Launch of the blood tests will help companies focused on developing preventive treatments make billions.
The Zacks Analyst Blog Highlights: United States Steel, Allegheny, Century, Astrazeneca and Ferrari
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United States Steel, Allegheny, Century, Astrazeneca and Ferrari
Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View
by Zacks Equity Research
Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.
Stocks to Buy & Avoid If Trump Slaps Import Tariffs
by Sweta Killa
The import curbs could lead to few winners but a number of losers from various corner of the equity space if the tariff is slapped.
Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer
by Zacks Equity Research
Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.
Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm
by Zacks Equity Research
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
by Zacks Equity Research
FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint
by Swarup Gupta
Losses on Wall Street and falling bond yields weighed on global markets this week.